Quantcast
Last updated on April 23, 2014 at 21:24 EDT

Latest Fluticasone/salmeterol Stories

2014-04-15 08:29:35

OXFORD, England and PITTSBURGH, April 15, 2014 /PRNewswire/ -- Prosonix, an innovative speciality pharmaceutical company developing a portfolio of inhaled Respiratory Medicines by Design, today announced that it has entered into a global licensing agreement with Mylan Inc. (Nasdaq: MYL), one of the world's leading global pharmaceutical companies, for its leading inhaled respiratory products, PSX1001 and PSX1050. PSX1001 and PSX1050, which are the first products to emerge from Prosonix's...

2014-04-01 08:27:28

LONDON, April 1, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:Inhalation & Nasal Spray Generic Drugs 2013 Around three quarters of the US$36.4 billion respiratory prescription drugs market comprises drugs that are delivered using inhalation or nasal spray technologies. The top five drugs used in the treatment of asthma and chronic obstructive pulmonary disease (COPD) attracted combined revenues of around US$18.0 billion in 2012. All five are...

2014-03-05 12:27:59

Asthma Drugs Face More Scrutiny in Insurance Exchanges, According to Findings from Decision Resources Group BURLINGTON, Mass., March 5, 2014 /PRNewswire/ -- Decision Resources Group finds that as the Affordable Care Act drives up the demand for asthma drugs, exchange-based plans will impose more cost controls and prescribing barriers than commercial plans, although the differences may not be dramatic. Results of a survey of 100 pulmonologists and 40 medical directors and pharmacy directors of...

2013-12-18 08:29:11

Generic Erosion of Market Leaders Will Be Offset by the First Once-Daily LABA/ICS Combination and Emerging Anticytokine Agents, According to Findings from Decision Resources BURLINGTON, Mass., Dec. 18, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the drug market for asthma will remain relatively flat through 2022. Currently, the market is driven by maintenance therapies that...

2013-11-27 15:20:34

A popular combination asthma therapy dogged by safety concerns has not harmed British Columbians and should remain in use, according to researchers at the University of British Columbia and Vancouver Coastal Health Research Institute. The therapy combines an inhaled corticosteroid to reduce swelling in the airways with "long-acting beta agonists" (LABAs) to ease breathing and reduce the risk of a severe asthma attack. The U.S. Food and Drug Administration (FDA), reacting to claims that...

2013-10-31 23:23:19

MedicationDiscountCard.com Now Offers Minastrin 24 Fe Coupon Margate, NJ (PRWEB) October 31, 2013 Health care expenses are on everybody's mind these days. With the coming implementation of the Affordable Care Act, there's a lot of talk about what it will do to the cost of healthcare—especially for those who already have health insurance. Studies show that 98% of sexually active women aged 15-44 have used some method of birth control. While birth control pills offer more...

2013-08-28 08:24:53

LABA/LAMA Fixed-Dose Combinations Will Achieve Over 35 Percent of COPD Sales in 2022, According to Findings from Decision Resources BURLINGTON, Mass., Aug. 28, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the drug market for chronic obstructive pulmonary disease (COPD) therapies will see the emergence of a new drug class that will drive sales through 2022. Currently, the COPD...

2013-07-01 08:27:49

Payers are Most Receptive to Reimbursing Premium-Priced Novel Therapies that Offer Clinical Improvements in the Rate of Severe Exacerbations, According to a New Report from Decision Resources BURLINGTON, Mass., July 1, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed pulmonologists in the United States and Europe agree that a drug's effect on reducing the exacerbation rate is...

2013-06-17 08:28:01

MISSISSAUGA, ON, June 17, 2013 /CNW/ - A second analysis of data from real-world study PATHOS, recently published in the British Medical Journal, shows that treatment of chronic obstructive pulmonary disease (COPD) patients with SYMBICORT(®) (budesonide/formoterol) was associated with a lower incidence of pneumonia and pneumonia related death, compared to treatment of COPD patients with ADVAIR(®) (fluticasone/salmeterol).(i) PATHOS is the largest real-world study to compare the...

2013-05-20 12:24:37

Phase III Clinical Data Indicate That Indacaterol/Glycopyrronium Has Advantages Over Current Therapies for Efficacy, According to a New Report from Decision Resources BURLINGTON, Mass., May 20, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. and European pulmonologists agree that therapies offering a greater effect on quality of life is among the areas of highest unmet...